Lamictal®

Glaxo Wellcome Inc. has received reports of prescription dispensing errors involving LAMICTAL® (lamotrigine) Tablets and LAMISIL® (terbinafine hydrochloride) Tablets. Lamictal®, which is distributed by Glaxo Wellcome, has been marketed since 1995. Lamisil Tablets were introduced into the market in 1996 by Novartis Pharmaceuticals Corp., although Lamisil Cream has been commercially available for years. These reports involve dispensing Lamictal® when Lamisil was prescribed and the reverse scenario.

Patients with epilepsy who do not receive Lamictal® due to a dispensing error would be inadequately treated and could experience serious consequences. Conversely, patients erroneously receiving Lamictal® would be unnecessarily subjected to a risk of potential side effects (including serious rash). This is especially true if patients received an initial high dose of Lamictal®

Source: fda.gov

If you or a loved one has been harmed by Lamictal®, you may want to contact a Lamictal® attorney for more information.